Carboplatin and Docetaxel Chemotherapy in Nasopharyngeal Carcinoma: A Case Report

Authors

  • Denny Satria Utama Department of Otorhinolaryngology Head And Neck Surgery Faculty of Medicine Universitas Sriwijaya /RSUP Dr. Moehammad Hoesin Palembang

DOI:

https://doi.org/10.32734/ijnpc.v3i01.5725

Keywords:

Nasopharyngeal carcinoma, chemotherapy, carboplatin, docetaxel

Abstract

Introduction:

Nasopharyngeal Carcinoma (NPC) is a squamous cell malignant tumor that usually occurs in the lateral wall of the nasopharynx near the area of the eustachian tube. NPC is often found in southern Asia. In head and neck areas, NPC is one of the top five malignant which has the highest frequency tumours in Indonesia.

Case report:

We reported a case of a 57-year-old man with complaints of obstruction in both noses, accompanied by headache. Based on medical history, physical and Radiology examination, we concluded that he was diagnosed with Nasopharyngeal Carcinoma WHO II Stage III (T3N0M0). Histopathology revealed a differentiated non keratinizing squamous cell carcinoma in the nasopharynx. Six cycles of carboplatin and docetaxel regimen as an induction chemotherapy were planned for this patient. The patient then performed a nasoendoscopy followed by nasopharyngeal CT scan evaluation and showed a good response after Chemotherapy.

Conclusion:

Carboplatin and docetaxel chemotherapy management in this patient was given according to the management of nasopharyngeal carcinoma and has given a good response to the patient

Downloads

Download data is not yet available.

References

Salehiniya H, Mohammadian M, Mohammadian-Hafshejani A, Mahdavifar N. Nasopharyngeal cancer in the world: epidemiology, incidence, mortality and risk factors. World cancer research journal. 2018 Oct 15;5(1). DOI: https://doi.org/10.32113/wcrj_20183_1046

Wei WI, Chua DT. Nasopharyngeal carcinoma. In: Bailey BJ, Johnson JT, Newland SD, editors. Head and neck surgery-otolaryngology. 5th Edition. Philadelphia: Lippincott Williams and Wilkins. 2015.1875-95

Mangunkusumo E. Buku Teks Komprehensif Ilmu THT-KL. Jakarta: EGC. 2019. 502-508

Kanno M, Narita N, Fujimoto Y, Wakisaka N, Yoshizaki T, Kodaira T, Makita C, Sato Y, Yamazaki K, Wakaoka T, Shimode Y. Third Epidemiological Analysis of Nasopharyngeal Carcinoma in the Central Region of Japan from 2006 to 2015. Cancers. 2019 Aug;11(8):1180. DOI: https://doi.org/10.3390/cancers11081180.

Wang KH, Austin SA, Chen SH, Sonne DC, Gurushanthaiah D. Nasopharyngeal carcinoma diagnostic challenge in a nonendemic setting: Our experience with 101 patients. The Permanente Journal. 2017;21. DOI: https://doi.org/10.7812/TPP/16-180.

Al-Azri A, Al-Sheibani S. Nasopharyngeal Carcinoma in Oman: A descriptive analysis. Oman medical journal. 2015 May;30(3):167. DOI: https://doi.org/10.5001/omj.2015.37

Dewi YA, Permana AD. Karsinoma nasofaring: presentasi klinis dan diagnosis. EGC. 2020; 85-6.

Miah AB, Bhide SA, Del Rosario L, Matthews J, Nicol R, Tanay MA, Gupta S, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM. Induction chemotherapy followed by chemo-intensity-modulated radiotherapy for locally advanced nasopharyngeal cancer. Clinical Oncology. 2016 Aug 1;28(8):e61-7. DOI: https://doi.org/10.1016/j.clon.2016.01.012

Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. The Lancet. 2016 Mar 5;387(10022):1012-24. DOI: https://doi.org/10.1016/S0140-6736(15)00055-0

Ch Chen YP, Chan AT, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. The Lancet. 2019 Jul 6;394(10192):64-80. DOI: https://doi.org/10.1016/S0140-6736(19)30956-0

David G, Sharon S, Douglas A. National Comprehensive Cancer Network (NCCN) Guidelines Head and Neck Cancers Versions 1. 2021. P 37-42

Bhattacharyya T, Babu G, Kainickal CT. Current role of chemotherapy in nonmetastatic nasopharyngeal cancer. Journal of oncology. 2018 Oct 1;2018.. DOI. https://doi.org/10.1155/2018/3725837

Mané M, Benkhaled S, Dragan T, Paesmans M, Beauvois S, Lalami Y, Szturz P, Gaye PM, Vermorken JB, Van Gestel D. Meta‐Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma. The oncologist. 2021 Jan;26(1):e130-41.. DOI: https://doi.org/10.1002/ONCO.13520. Epub 2020 Oct 1

Xu C, Zhang S, Li WF, Chen L, Mao YP, Guo Y, Liu Q, Ma J, Tang LL. Selection and validation of induction chemotherapy beneficiaries among patients with T3N0, T3N1, T4N0 nasopharyngeal carcinoma using Epstein-Barr virus DNA: a joint analysis of real-world and clinical trial data. Frontiers in oncology. 2019 Nov 29;9:1343. DOI: https://doi.org/10.3389/fonc.2019.01343. eCollection 2019.

Liao JF, Zhang Q, Du XJ, Lan M, Liu S, Xia YF, Cai XY, Luo W. Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score‐matched analysis. Cancer Communications. 2019 Dec;39(1):1-1. DOI: https://doi.org/10.1186/s40880-019-0380-x

Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Sumitsawan Y, Tharavichitkul E, Sukthomya V, Ford J. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. European journal of cancer. 2007 Jun 1;43(9):1399-406. DOI: https://doi.org/10.1016/j.ejca.2007.03.022

Ngaimphaiboon N, Dechaphunkul A, Danchaivijitr P, Jiratrachu R, Dechaphunkul T, Sookthon C, Jiarpinitnun C, Paoin C, Setakornnukul J, Suktitipat B, Pattaranutaporn P. Comparison of 3-weekly cisplatin versus 3-weekly carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicentre analysis. DOI: https://doi.org/10.1200/JCO.2017.35.15_suppl.6006cita

Published

2021-03-20

How to Cite

1.
Utama DS. Carboplatin and Docetaxel Chemotherapy in Nasopharyngeal Carcinoma: A Case Report. IJNPC [Internet]. 2021Mar.20 [cited 2021May11];3(01):25-7. Available from: https://talenta.usu.ac.id/IJNPC/article/view/5725